WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009136031) USE OF AN ANTI-CD151 ANTIBODY FOR EARLY TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/136031    International Application No.:    PCT/FR2009/050561
Publication Date: 12.11.2009 International Filing Date: 02.04.2009
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01)
Applicants: PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel Gance F-92100 Boulogne (FR) (For All Designated States Except US).
HAEUW, Jean-François [FR/FR]; (FR) (For US Only)
Inventors: HAEUW, Jean-François; (FR)
Agent: ROUSSEAU, Pierick; (FR)
Priority Data:
0801865 04.04.2008 FR
Title (EN) USE OF AN ANTI-CD151 ANTIBODY FOR EARLY TREATMENT OF CANCER
(FR) UTILISATION D'UN ANTICORPS ANTI-CD151 POUR LE TRAITEMENT PRECOCE DES CANCERS
Abstract: front page image
(EN)The invention relates to the use of at least one antibody, or one of its functional fragments, that can bind to the protein CD151, thereby inhibiting tumour growth, for preparing a medicament for the early treatment of cancer. The invention also relates to a composition for treating cancer, comprising at least one anti-CD151 antibody, or one of the functional fragments thereof, as an active principle, that can bind to the protein CD151 and/or inhibit its metastasis-promoting activity, said antibodies being the antibodies secreted by the hybridoma filed at the ATCC under the number CRL-2696.
(FR)La présente invention a pour objet l'utilisation d'au moins un anticorps, ou l'un de ses fragments fonctionnels, capable de se lier à la protéine CD151 et ainsi d'inhiber la croissance tumorale pour la préparation d'un médicament destiné au traitement précoce du cancer. L'invention vise également un composition pour le traitement du cancer, comprenant à titre de principe actif au moins un anticorps anti-CD151, ou l'un de ses fragments fonctionnels, capable de se lier à la protéine CD151 et/ou d'inhiber son activité promotrice de métastase, lesdits anticorps consistant en les anticorps sécrétés par l'hybridome déposé à l'ATCC sous le numéro CRL-2696.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: French (FR)
Filing Language: French (FR)